Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
PURPOSE: The prognostic significance of ATM mutations in chronic lymphocytic leukemia (CLL) is unclear. We assessed their impact in the context of a prospective randomized trial. PATIENTS AND METHODS: We analyzed the ATM gene in 224 patients treated on the Leukemia Research Fund Chronic Lymphocytic...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797087547929657344 |
|---|---|
| author | Skowronska, A Parker, A Ahmed, G Oldreive, C Davis, Z Richards, S Dyer, M Matutes, E Gonzalez, D Taylor, A Moss, P Thomas, P Oscier, D Stankovic, T |
| author_facet | Skowronska, A Parker, A Ahmed, G Oldreive, C Davis, Z Richards, S Dyer, M Matutes, E Gonzalez, D Taylor, A Moss, P Thomas, P Oscier, D Stankovic, T |
| author_sort | Skowronska, A |
| collection | OXFORD |
| description | PURPOSE: The prognostic significance of ATM mutations in chronic lymphocytic leukemia (CLL) is unclear. We assessed their impact in the context of a prospective randomized trial. PATIENTS AND METHODS: We analyzed the ATM gene in 224 patients treated on the Leukemia Research Fund Chronic Lymphocytic Leukemia 4 (LRF-CLL4) trial with chlorambucil or fludarabine with and without cyclophosphamide. ATM status was analyzed by denaturing high-performance liquid chromatography and was related to treatment response, survival, and the impact of TP53 alterations for the same patient cohort. RESULTS: We identified 36 ATM mutations in 33 tumors, 16 with and 17 without 11q deletion. Mutations were associated with advanced disease stage and involvement of multiple lymphoid sites. Patients with both ATM mutation and 11q deletion showed significantly reduced progression-free survival (median, 7.4 months) compared with those with ATM wild type (28.6 months), 11q deletion alone (17.1 months), or ATM mutation alone (30.8 months), but survival was similar to that in patients with monoallelic (6.7 months) or biallelic (3.4 months) TP53 alterations. This effect was independent of treatment, immunoglobulin heavy chain variable gene (IGHV) status, age, sex, or disease stage. Overall survival for patients with biallelic ATM alterations was also significantly reduced compared with those with ATM wild type or ATM mutation alone (median, 42.2 v 85.5 v 77.6 months, respectively). CONCLUSION: The combination of 11q deletion and ATM mutation in CLL is associated with significantly shorter progression-free and overall survival following first-line treatment with alkylating agents and purine analogs. Assessment of ATM mutation status in patients with 11q deletion may influence the choice of subsequent therapy. |
| first_indexed | 2024-03-07T02:37:11Z |
| format | Journal article |
| id | oxford-uuid:a930e833-e06c-4430-9f43-b4e11fd17e85 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:37:11Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:a930e833-e06c-4430-9f43-b4e11fd17e852022-03-27T03:06:44ZBiallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a930e833-e06c-4430-9f43-b4e11fd17e85EnglishSymplectic Elements at Oxford2012Skowronska, AParker, AAhmed, GOldreive, CDavis, ZRichards, SDyer, MMatutes, EGonzalez, DTaylor, AMoss, PThomas, POscier, DStankovic, TPURPOSE: The prognostic significance of ATM mutations in chronic lymphocytic leukemia (CLL) is unclear. We assessed their impact in the context of a prospective randomized trial. PATIENTS AND METHODS: We analyzed the ATM gene in 224 patients treated on the Leukemia Research Fund Chronic Lymphocytic Leukemia 4 (LRF-CLL4) trial with chlorambucil or fludarabine with and without cyclophosphamide. ATM status was analyzed by denaturing high-performance liquid chromatography and was related to treatment response, survival, and the impact of TP53 alterations for the same patient cohort. RESULTS: We identified 36 ATM mutations in 33 tumors, 16 with and 17 without 11q deletion. Mutations were associated with advanced disease stage and involvement of multiple lymphoid sites. Patients with both ATM mutation and 11q deletion showed significantly reduced progression-free survival (median, 7.4 months) compared with those with ATM wild type (28.6 months), 11q deletion alone (17.1 months), or ATM mutation alone (30.8 months), but survival was similar to that in patients with monoallelic (6.7 months) or biallelic (3.4 months) TP53 alterations. This effect was independent of treatment, immunoglobulin heavy chain variable gene (IGHV) status, age, sex, or disease stage. Overall survival for patients with biallelic ATM alterations was also significantly reduced compared with those with ATM wild type or ATM mutation alone (median, 42.2 v 85.5 v 77.6 months, respectively). CONCLUSION: The combination of 11q deletion and ATM mutation in CLL is associated with significantly shorter progression-free and overall survival following first-line treatment with alkylating agents and purine analogs. Assessment of ATM mutation status in patients with 11q deletion may influence the choice of subsequent therapy. |
| spellingShingle | Skowronska, A Parker, A Ahmed, G Oldreive, C Davis, Z Richards, S Dyer, M Matutes, E Gonzalez, D Taylor, A Moss, P Thomas, P Oscier, D Stankovic, T Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title | Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title_full | Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title_fullStr | Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title_full_unstemmed | Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title_short | Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. |
| title_sort | biallelic atm inactivation significantly reduces survival in patients treated on the united kingdom leukemia research fund chronic lymphocytic leukemia 4 trial |
| work_keys_str_mv | AT skowronskaa biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT parkera biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT ahmedg biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT oldreivec biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT davisz biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT richardss biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT dyerm biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT matutese biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT gonzalezd biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT taylora biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT mossp biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT thomasp biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT oscierd biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial AT stankovict biallelicatminactivationsignificantlyreducessurvivalinpatientstreatedontheunitedkingdomleukemiaresearchfundchroniclymphocyticleukemia4trial |